Dr Chae-Ok Yun
Associate Editor: Chae-Ok Yun
Chae-Ok Yun is currently a Professor of Bioengineering at Hanyang University, Seoul, Korea. She is also an Adjunct Professor of Pharmaceuticals and Pharmaceutical Chemistry at University of Utah, Salt Lake City, United States, an Affiliate Professor of Medicine at University of Washington, United States, a Guest Professor of Sichuan University, China, and an Adjunct Professor of Genomics at Yonsei University. She received her BS (1986) and MS (1988) degree in Molecular Biology from Sogang University, Seoul, Korea. In 1996, she received her Ph.D. degree in Molecular and Cellular Biology from Illinois Institute of Technology, Chicago, United States. From 1996 to 1998, she completed a postdoctoral fellowship in Hematology and Oncology at Harvard Medical School, Boston, and then served as a Research Associate in Radiation Oncology at Harvard Medical School, Boston, until 2000. She next moved back to Seoul, Korea where she was firstly Assistant Professor (2000), Associate Professor (2005), Professor (2010) at Yonsei University College of Medicine, and then Professor (2011) at Hanyang University.
She has served as Deputy Editor of Molecular Therapy (2010-), Associate Editor of BMC Cancer (2010-) and Cancer Gene Therapy (2013-), and Editorial Board member of Journal of Controlled Release (2010-), Gene Therapy and Regulation (2010-), Oncolytic Virotherapy (2012-), International Journal of Cancer Research & Diagnosis (2013-), Regenerative Therapy(2016-), and Advanced Drug Delivery Review (2016-),.
She was awarded the Excellence in Research Award from the American Society of Gene Therapy in 2002 and Excellent Professor in Research Achievement from Yonsei University in 2003, 2005, 2007, 2008, and 2011. She received the Bowon Award for Best Research Activity from Yonsei University in 2007. She also was awarded the Excellence in Research Award from Korean Society of Gene Therapy (2011, 2012, and 2014) and Korean Government Ministry award from Ministry of Science (2013). Her research interests include cancer gene therapy, immunotherapy, angiogenesis, combination of viral vectors and non-viral vectors, nanomedicine, and tumor biology. One of her gene therapeutics is in clinical trials against cancer patients.